Nivalis Therapeutics, Inc. (ALPN)
(Delayed Data from NSDQ)
$6.24 USD
-0.08 (-1.27%)
Updated May 3, 2019 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ALPN 6.24 -0.08(-1.27%)
Will ALPN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALPN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALPN
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
Vertex's (VRTX) Q1 Earnings Beat, Trikafta Drives Sales
ALPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex